Mifobate

Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD) -induced PPARγ transcriptional activity (IC50=140 μM) . Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR) . Mifobate (SR-202) shows antiobesity and antidiabetic effects[1].

Product Specifications

CAS Number

[76541-72-5]

Product Name Alternative

SR-202

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/mifobate.html

Purity

99.85

Solubility

H2O : 35.87 mg/mL (ultrasonic; warming) |DMSO : 100 mg/mL (ultrasonic)

Smiles

O=P(OC)(OC)OC(C1=CC=C(Cl)C=C1)P(OC)(OC)=O

Molecular Formula

C11H17ClO7P2

Molecular Weight

358.65

Precautions

H302, H315, H319, H335

References & Citations

[1]Rieusset J, et al. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesityand antidiabetic activity. Mol Endocrinol. 2002 Nov;16 (11) :2628-44.